4d Pharma PLC (DDDD.L) Final Results

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, is pleased to announce the final results for the Group for the year ended 31 December 2019.

Financial highlights for the year:

· Net assets of £22.3 million (2018: £45.8 million)

· Cash and cash equivalents (including cash on deposit) of £3.8 million (2018: £26.2 million)

· Total comprehensive loss after tax of £23.7 million (2018: £24.3 million)

· Adjusted loss per share of 40.81 pence (2018: 36.17 pence)

· Basic and diluted loss per share of 36.75 pence (2018: 36.17 pence)

Operational highlights for the year:

· First-in-class data in oncology – positive safety and preliminary clinical observations of lead immuno-oncology candidate MRx0518 in combination with Keytruda®

· Entered a research collaboration and option agreement with MSD (Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA) to use the MicroRx® discovery platform to develop Live Biotherapeutics in the vaccines space , including an upfront payment and potential milestone payments totalling >$1 billion

· MSD collaboration included commitment to equity investment in 4D by MSD, triggered after period end

· Launched a Phase I/II trial of MRx-4DP0004 in partly controlled asthma – the first clinical trial of a single strain Live Biotherapeutic in this indication

· Expanded our Board of Directors, adding clinical and commercial expertise from both Europe and US

Since the period end:

· In early January 2020 we launched our third trial of MRx0518, in pancreatic cancer in combination with radiotherapy

· In February 2020 4D completed a placing and subscription raising gross proceeds of £22 million

· In April 2020 we announced interim results from an ongoing Phase II trial of Blautix® in IBS-C or IBS-D

· In April 2020 we received expedited approval from the MHRA for a Phase II clinical trial of immunomodulatory Live Biotherapeutic MRx-4DP0004 to treat COVID-19 patients

Axel Glasmacher, Chairman of 4D pharma, commented “I am pleased to be able to announce the Group’s final results for the year ended 31 December 2019. 2019 was a successful year for the Group in which we made great progress in the clinic across multiple programmes, and entered collaborations with new partners. I would like to thank everyone in the Group for their valuable contributions as we look ahead to a pivotal year for 4D as we reach key readouts from multiple clinical studies.”

Duncan Peyton, Chief Executive Officer, commented “Over the past year we made impressive progress in all aspects of our business, towards the delivery of a new class of drug, Live Biotherapeutics. We now look forward to the year having set up multiple near-to-mid-term catalysts as we generate robust clinical data with multiple shots on goal. ”

The Annual Report, together with a notice of the Company’s Annual General Meeting (“AGM”), will be posted to shareholders and made available on the Company’s website, www.4dpharmaplc.com, on 4 June 2020. The Annual General Meeting will be held on Tuesday 30 June 2020 at 10 a.m. at 9 Bond Court, Leeds, LS1 2JZ. In light of the current guidance from the UK Government which prevents public gatherings of more than two people, shareholders, advisers and other guests will not be allowed to attend the AGM and anyone seeking to attend the meeting in person will be refused entry. We therefore encourage shareholders to submit any questions they would like to pose to the Board to ir@4dpharmaplc.com so as to be received no later than 26 June 2020. All emails should be marked “AGM Question” in the subject line, and will require a shareholder number. If the UK Government’s guidance changes before the AGM and allows gatherings of more than two people, we will notify you via the Company’s website at www.4dpharmaplc.com


Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates.

Terms of Website Use

All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Time Management Software For Stock Market Investments Time Management Software For Stock Market Investments
Share via
Copy link
Malcare WordPress Security